- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biocon Gains EU Authorization for Insulin Aspart Biosimilar
The Bengaluru, India, company said the fast-acting biosimilar will improve affordability of insulin in Europe, which also faces rising prices and access problems.
The European Commission (EC) has approved an insulin aspart biosimilar (Kixelle) for marketing. The product is a fast-acting insulin developed by Biocon Biologics, of Bengaluru, India.
Kixelle is indicated for the treatment of diabetes in adults, adolescents, and children at least 1 year of age. It was approved as a 100 units/mL solution for injection and will be available in vials and prefilled pens.
"The approval will enable affordable access to a rapid-acting insulin analog for people with diabetes in the EU [European Union], where our biosimilar insulin glargine, a long-acting insulin analog, is already addressing patients’ needs for an affordable quality treatment option,” Biocon said in a statement. The insulin glargine product, a longer-acting insulin, is Semglee (referencing Lantus), which is also available in the United States via a Biocon partnership with Viatris.
Biocon said the authorization allows distribution of the product in all EU member states and Iceland, Liechtenstein, and Norway, which are in the European Economic Area.
The Kixelle EC approval decision arrived as scheduled for Biocon and its partner in the project, Viatris, which anticipated an early 2021 authorization following a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
